Thomas Weisel Ups Biogen Idec to Peer Perform

Analyst Ian Somaiya expects the FDA to approve Tysabri by March 29

Thomas Weisel upgraded Biogen Idec (BIIB) to peer perform from underperform, after the Food and Drug Administration on Wednesday voted unanimously to recommend reintroduction of Tysabri as a treatment for relapsing forms of multiple sclerosis.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.